Skip navigation

Prostate carcinoma

Prostate carcinoma (PCa) is a malignant tumour disease that originates in the glandular tissue of the prostate gland. Frequency: PCa is the most common malignant tumour in men and the third most frequent cause of death due to carcinoma in Germany. The frequency increases with age. The aetiology of prostate carcinoma and progression of the disease is unknown. The PCa usually grows very slowly, initially within the prostate. Only when the prostate capsules are crossed can the disease progress locally. Preferred metastasis areas are the retroperitoneal lymph nodes and the axial skeleton.

Treatment / Surgury

Selection of the appropriate therapy method depends on the tumour stage, the age of the patient, and any comorbidities. However, numerous individual factors are also to be considered, such as the patient's preference.

  1. Active surveillance
    Waiting, only intervening with a curative treatment once the tumour has progressed, is a possible treatment option for a locally limited PCa in the early stage, under precisely defined conditions.
  2. Radical prostatovesiculectomy
    Removal of the prostate and the seminal vesicles will be considered, particularly given a local PCa without clinically recognisable metastases; this can be done using different surgical techniques (retropubically or laparoscopically) with possible preservation of the erection nerves.
  3. Radiotherapy
    Percutaneous radiotherapy and brachytherapy (insertion of seeds into the prostate) can be used with localized and locally advanced PCa without remote metastases; the prerequisite, however, is an undisturbed emptying of the bladder without formation of residual urine.
  4. Watchful waiting
    In certain situations, especially for elderly patients with severe comorbidities, it may also be useful to dispense with primarily stressful tumour therapy and instead to wait for tumour-related complaints, and to treat these palliatively.
  5. Hormone therapy
    Androgen removal should be performed for advanced and metastasised PCa as a palliative treatment option, which is medically treated using an LH-RH analogue. However, combination with an antiandrogen is also possible.
  6. Chemotherapy
    Treatment with cytotoxic drugs, for example docetaxel or newer products such as abiraterone or enzalutamide, is recommended if antiandrogen therapy has lost its efficacy (in a hormone-refractory situation).



Clinic and Polyclinic for Urology

PD Dr. Uwe Zimmermann


Clinic and Polyclinic for Urology

PD Dr. Maik Pechoel


Tamara Usichenko
Geschäftsbereich Patientenmanagement
Universitätsmedizin Greifswald
Fleischmannstr. 8
17475 Greifswald

Phone: +49 3834 86-5184
Mobil: +49 151 55459980
E-Mail: international.patientsmed.uni-greifswaldde